This four-episode podcast is designed to identify and analyze the educational needs and practice gaps that exist among healthcare practitioners who are involved in the diagnosis and management of patients with Alzheimer’s disease. This program will educate participants on providing a timely diagnosis, referral, and appropriate treatment. We will hear from a primary care physician, a neurologist, a geriatrician, and a geriatric psychiatrist on the importance of multidisciplinary care and shared decisions in the diagnosis and treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD).

RELEASED DATE: April 25, 2025
EXPIRATION DATE: May 09, 2026

This program aims to enable clinicians to help improve care of patients with mild cognitive/behavioral impairment and Alzheimer’s disease through (1) discussion of strategies to overcome barriers to the timely diagnosis of Alzheimer’s disease; (2) applying quantitative assessments and integrating neuroimaging and specialty referral in clinical assessment; and (3) building skills to improve multidisciplinary communication and shared decision-making with patients.

RELEASED DATE: June 07, 2024
EXPIRATION DATE: June 07, 2025

This interactive TeleECHO program is designed to provide clinicians who manage patients with Alzheimer’s disease (AD) with up-to-date information on the early diagnosis and treatment in these patients, using strategies to address stigma, apply quantitative assessments, and integrate neuroimaging in clinical assessment; optimal multidisciplinary communication and specialty referral; integration of clinical data updates to inform early identification of AD; and shared decision-making (SDM) approaches with patients and caregivers to facilitate diagnosis and optimize care plans.

RELEASED DATE: May 31, 2024
EXPIRATION DATE: May 31, 2025

This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with current information on diagnosis and management, including the impact of the disease on caregivers.

RELEASED DATE: June 17, 2024
EXPIRATION DATE: July 17, 2025

This enduring activity is designed to help Alzheimer’s disease and dementia providers diagnose AD earlier in the disease course through comprehensive history, physical and quantitative assessments, neuroimaging, and referral when appropriate. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary and clinician/patient communication to facilitate the best possible treatment outcomes.

RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025

This enduring activity is designed to help Alzheimer’s disease providers diagnose AD earlier in the disease course through comprehensive history and physical, quantitative assessments, neuroimaging, and referral, when appropriate. Our faculty will assist learners in developing strategies to improve multidisciplinary and clinician/patient communication to facilitate the best possible treatment outcomes.

RELEASED DATE: July 31, 2024
EXPIRATION DATE: July 31, 2025

This enduring activity is designed to provide learners with important clinical information on screening, diagnosing, and staging mild cognitive impairment and Alzheimer’s disease. The content will address clinical practice recommendations informing the use of disease-modifying therapy for Alzheimer’s disease, and provide tools on how to assess and manage potential adverse events associated with these agents. Finally, this educational program will help clinicians apply best practices for shared decision making.

RELEASED DATE: March 10, 2025
EXPIRATION DATE: March 10, 2026

This educational initiative is designed for pharmacists in the United States and globally who are involved in the care of patients with early symptomatic Alzheimer's disease (MCI due to AD, or mild dementia due to AD). It uses a multi-component platform – the DETECT Initiative – to increase learner ability to: review evolving clinical data informing the use of anti-amyloid therapeutics (ATTs) in the care of patients with AD, including mechanisms, efficacy, safety, and dosing and administration best practices; apply best practices for individualized patient counseling to ensure adequate monitoring and management in the provision of ATTs; design guideline-informed evidence-based protocols for preparation, dosing, and scheduling of ATTs in the clinical settings; and facilitate the management of financial and reimbursement issues for patients receiving ATTs.

RELEASED DATE: March 12, 2025
EXPIRATION DATE: March 12, 2026